The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.

Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

Insmed (NASDAQ:INSM) reported 12-month results from an ongoing open-label extension study of TPIP in patients with pulmonary arterial hypertension, saying the data showed sustained efficacy measures and a generally favorable safety profile over longer-term use. TPIP is an inhaled prodrug of trepros

Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study

TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Strategy fell 7.72% (net) in the quarter compared to -6.35% for the Russell Midcap Growth Index. In the first quarter, markets navigated geopolitical tensions and economic resilience alongside […]

Here’s Why TimesSquare Mid Cap Growth Strategy Added Insmed (INSM)

Insmed Incorporated (NASDAQ:INSM) is among the Best Healthcare Stocks. On June 15, Mizuho lowered its price target on Insmed Incorporated (NASDAQ:INSM) to $192 from $202. It maintained an Outperform rating on the shares. The firm stated the recent selloff created a buying opportunity even though shares have fallen 29% since the company’s first-quarter report. Mizuho found […]

Mizuho Maintains an Outperform Rating on Insmed Incorporated (INSM)

Nabius and CoreWeave surged in the lead up to their Nasdaq 100 listing, but have fallen in the to days since their inclusions.

Nebius and CoreWeave fall after Nasdaq 100 listing

Kymera Therapeutics (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?

Insmed Incorporated was removed from the NASDAQ-100 Index on 19 June 2026, even as investor focus intensified on its experimental lung drug TPIP. Analyst commentary now emphasizes TPIP’s upcoming clinical data as a potential turning point for Insmed’s rare respiratory disease portfolio and overall outlook. We’ll now examine how heightened expectations around TPIP’s upcoming data release may reshape Insmed’s existing clinical and earnings narrative. We've uncovered the 7 dividend fortresses...

Should Insmed’s (INSM) NASDAQ-100 Exit and TPIP Focus Require Action From Investors?

Insmed Incorporated (NASDAQ:INSM) is one of the most promising healthcare stocks according to Wall Street analysts. On June 10, Cantor Fitzgerald reaffirmed its Overweight rating on Insmed Incorporated (NASDAQ:INSM) and raised its price target from $230 to $235. The firm pointed to an upcoming data release for Insmed’s experimental lung drug TPIP as a potential […]

Is Insmed (INSM) One of the Most Promising Healthcare Stocks After Cantor Fitzgerald’s Target Raise?

Incyte has rallied the healthcare sector over the past year, and analysts remain moderately optimistic about its prospects.

Incyte Stock: Is INCY Outperforming the Healthcare Sector?

This morning, the Nasdaq-100 is getting its quarterly rebalance with five firms getting the boot and five taking their place.

Insider Name	Relation to Company	Shares Changed	Price	Transaction Date
LEWIS WILLIAM H	Chief Executive Officer	21,398	$2.21	Jun 25, 2026
BUTERA SAMUELE	Officer	7,342	$N/A	Jun 23, 2026
SMITH MICHAEL ALEXANDER	Officer	1,806	$0.17	Jun 22, 2026
LEWIS WILLIAM H	Chief Executive Officer	6,515	$0.61	Jun 8, 2026
FLAMMER MARTINA	Officer	4,424	$0.46	Jun 5, 2026
SMITH MICHAEL ALEXANDER	Officer	2,159	$0.22	Jun 3, 2026
LEWIS WILLIAM H	Chief Executive Officer	7,605	$0.78	Jun 3, 2026
BONSTEIN SARA M	Chief Financial Officer	2,404	$0.25	Jun 3, 2026
ADSETT ROGER	Chief Operating Officer	2,370	$0.24	Jun 3, 2026
SMITH MICHAEL ALEXANDER	Officer	6,149	$0.67	May 22, 2026

INSM(INSM)
NASDAQ

Company Profile & Information

Company Profile

Business Overview

Insider Transactions

Similar Companies

Analysis Tools

INSM(INSM)NASDAQ